Immix Biopharma (IMMX) Competitors $2.61 +0.06 (+2.35%) As of 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. TVGN, SLRN, CGC, NBTX, BTMD, MNPR, SLS, TVRD, PRQR, and NGNEShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Semper Paratus Acquisition (TVGN), Acelyrin (SLRN), Canopy Growth (CGC), Nanobiotix (NBTX), biote (BTMD), Monopar Therapeutics (MNPR), SELLAS Life Sciences Group (SLS), Tvardi Therapeutics (TVRD), ProQR Therapeutics (PRQR), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Semper Paratus Acquisition Acelyrin Canopy Growth Nanobiotix biote Monopar Therapeutics SELLAS Life Sciences Group Tvardi Therapeutics ProQR Therapeutics Neurogene Immix Biopharma (NASDAQ:IMMX) and Semper Paratus Acquisition (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Does the media prefer IMMX or TVGN? In the previous week, Semper Paratus Acquisition had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 2 mentions for Semper Paratus Acquisition and 1 mentions for Immix Biopharma. Semper Paratus Acquisition's average media sentiment score of 0.62 beat Immix Biopharma's score of 0.00 indicating that Semper Paratus Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Semper Paratus Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IMMX or TVGN more profitable? Semper Paratus Acquisition's return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -130.02% -86.33% Semper Paratus Acquisition N/A N/A -934.56% Do analysts prefer IMMX or TVGN? Immix Biopharma presently has a consensus target price of $7.00, indicating a potential upside of 168.20%. Semper Paratus Acquisition has a consensus target price of $10.00, indicating a potential upside of 729.88%. Given Semper Paratus Acquisition's higher possible upside, analysts clearly believe Semper Paratus Acquisition is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in IMMX or TVGN? 11.3% of Immix Biopharma shares are held by institutional investors. 55.4% of Immix Biopharma shares are held by company insiders. Comparatively, 73.2% of Semper Paratus Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, IMMX or TVGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$21.61M-$0.70-3.73Semper Paratus AcquisitionN/AN/A-$13.73MN/AN/A Which has more volatility and risk, IMMX or TVGN? Immix Biopharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Semper Paratus Acquisition has a beta of -0.73, indicating that its stock price is 173% less volatile than the S&P 500. SummarySemper Paratus Acquisition beats Immix Biopharma on 6 of the 9 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.77M$2.85B$5.44B$8.92BDividend YieldN/A2.44%5.22%4.00%P/E Ratio-3.7320.4927.2520.05Price / SalesN/A282.72426.50117.27Price / CashN/A41.7026.2128.59Price / Book5.447.407.925.57Net Income-$21.61M-$55.04M$3.17B$248.56M7 Day Performance26.09%3.67%4.48%7.44%1 Month Performance10.13%0.33%2.80%8.43%1 Year Performance10.59%4.79%35.04%21.72% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.1563 of 5 stars$2.61+2.4%$7.00+168.2%+8.3%$72.77MN/A-3.739News CoverageTVGNSemper Paratus Acquisition3.9589 of 5 stars$1.25+0.8%$10.00+700.0%+77.9%$229.86MN/A0.003SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CGCCanopy Growth2.8215 of 5 stars$1.22flat$2.00+63.9%-79.6%$224.32M$225.65M-0.303,150Positive NewsNBTXNanobiotix1.6775 of 5 stars$4.73+4.4%$8.00+69.1%-8.2%$222.93M$39.18M0.00100Positive NewsGap UpBTMDbiote3.0815 of 5 stars$4.02-4.3%$8.00+99.0%-43.0%$219.93M$197.19M6.59194MNPRMonopar Therapeutics2.8083 of 5 stars$35.78+6.5%$56.50+57.9%+896.3%$218.97MN/A-10.2810Analyst ForecastSLSSELLAS Life Sciences Group0.1151 of 5 stars$2.19+12.3%N/A+79.8%$218.52M$1M-5.7610High Trading VolumeTVRDTvardi TherapeuticsN/A$23.33-5.2%$71.50+206.5%N/A$218.37M$7.14M0.0080PRQRProQR Therapeutics2.1042 of 5 stars$2.04flat$8.00+292.2%+26.1%$214.63M$20.46M-5.83180NGNENeurogene3.6045 of 5 stars$14.95-7.5%$46.17+208.8%-41.3%$213.19M$930K-3.4490 Related Companies and Tools Related Companies Semper Paratus Acquisition Competitors Acelyrin Competitors Canopy Growth Competitors Nanobiotix Competitors biote Competitors Monopar Therapeutics Competitors SELLAS Life Sciences Group Competitors Tvardi Therapeutics Competitors ProQR Therapeutics Competitors Neurogene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
